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Abstract
Pentraxin 3 (PTX3) is a soluble pattern recognition receptor and an acute-phase protein. It has gained attention as a new biomarker
reﬂecting tissue inﬂammation and damage in a variety of diseases. Aim of this study is to investigate the role of PTX3 in childhood
asthma.
In total, 260 children (140 patients with asthma and 120 controls) were enrolled. PTX3 levels were measured in sputum
supernatants using enzyme-linked immunosorbent assay test. We performed spirometry and methacholine challenge tests and
measured the total eosinophil count and the serum levels of total IgE and eosinophil cationic protein (ECP) in all subjects.
Sputum PTX3 concentration was signiﬁcantly higher in children with asthma than in control subjects (P<0.001). Furthermore,
sputum PTX3 levels correlated with atopic status and disease severity among patients with asthma. A positive signiﬁcant correlation
was found between sputum PTX3 and the bronchodilator response (r=0.25, P=0.013). Sputum PTX3 levels were negatively
correlated with forced expiratory volume in 1second (FEV1) (r= -0.30, P=0.001), FEV1/forced vital capacity (FVC) (r= -0.27, P=
0.002), and FEF25–75 (r= -0.392, P<0.001), which are indicators of airway obstruction and inﬂammation. In addition, the PTX3
concentration in sputum showed negative correlations with post-bronchodilator (BD) FEV1 (r= -0.25, P<0.001) and post-BD FEV1/
FVC (r= -0.25, P<0.001), which are parameters of persistent airﬂow limitation reﬂecting airway remodeling.
Sputum PTX3 levels increased in children with asthma, suggesting that PTX3 in sputum could be a candidate molecule to evaluate
airway inﬂammation and remodeling in childhood asthma.
Abbreviations: AHR = airway hyperresponsiveness, ASMCs = airway smooth muscle cells, BD = bronchodilator, BDR =
bronchodilator response, COPD = chronic obstructive pulmonary disease, ECP = eosinophil cationic protein, FEF25–75 = forced
expiratory ﬂow mid-expiratory phase between 25% and 75% of forced vital capacity, FEV1 = forced expiratory volume in 1 second,
FEV1/FVC= ratio of forced expiratory volume in 1 second and forced vital capacity, FVC= forced vital capacity, IgE= immunoglobulin
E, PC20 = provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 second, PRR = pattern
recognition receptor, PTX = pentraxin.
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Asthma is the most common chronic airway inﬂammatory
disorder in children, characterized by variable airﬂow obstruc-
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Kim et al. Medicine (2016) 95:51 Medicinewith asthma remain undiagnosed or unclassiﬁed. Thus, new
diagnostic approaches and assessments have been under
investigation in childhood asthma, which can be a heterogeneous
disease characterized by various clinical symptoms and variable
progression of the underlying airway inﬂammation and struc-
tural alterations.[3]
Pentraxin 3 (PTX3) acts as a soluble pattern recognition
receptor (PRR) involved in innate immunity, and it is a member of
the long PTX subfamily. PTX3 is not only known as an acute
phase protein but also as a multifunctional protein, and several
studies have reported its role in various inﬂammatory diseases.
PTX3 has been studied as an emerging marker reﬂecting tissue
injury and inﬂammation, such as that caused by acute respiratory
distress syndrome,[4] atherosclerosis,[5] small-vessel vasculitis,[6]
rheumatoid arthritis,[7] chronic kidney disease,[8] and lupus
nephritis.[9] An association between PTX3 and chronic airway
inﬂammatory diseases has been also discovered.[10–14] However,
the precise role of PTX3 in chronic lung inﬂammation has not
been established, particularly in children.
This study aimed to determine whether PTX3 plays a role in
childhood asthma. We examined sputum PTX3 levels in children
with asthma and compared its levels among subgroups of
subjects. The relationships between sputum PTX3 levels and
other asthma indices, including blood and sputum biomarkers
and pulmonary function parameters, were also analyzed.2. Methods
2.1. Subjects
In total, 260 children were enrolled who visited Severance
Children’s Hospital between January 2012 and December 2014.
Among them, 140 were diagnosed with asthma on the basis of the
American Thoracic Society criteria, which deﬁne asthma as
recurrent wheezing or coughing in the absence of a cold in the
preceding 12months with a physician’s diagnosis, and AHRupon
methacholine challenge (PC20 16mg/mL) or at least 12%
reversibility of forced expiratory volume in 1second (FEV1) after
bronchodilator (BD).[15] Among the asthma patients, 72 were
diagnosed with intermittent asthma, 35 had mild persistent
asthma, and31hadmoderate-to-severepersistent asthma.Noneof
the asthmatic children had a history of acute respiratory infection
in the preceding 4 weeks or were receivingmaintenance therapy at
the time of enrollment. Children treated with systemic corticoste-
roids due to asthma exacerbation in the preceding month were
excluded. The control group consisted of 120 children who had
visited the hospital for a general health workup or vaccination and
had no history of wheezing, recurrent or chronic diseases, acute
infection in the preceding 4 weeks, or hyperresponsiveness to
methacholine. Total serum immunoglobulin E (IgE) levels,
peripheral blood eosinophil count, and eosinophil cationic protein
(ECP) levels were measured at the initiation of the evaluations.
Atopy was deﬁned as >0.7KUa/L of speciﬁc IgE to more than 1
allergen, or>150IU/mL total IgE, ormore than 1 positive skin test
among 12 common aeroallergens, including 2 types of house dust
mites, cat and dog epithelium, aswell asmold and pollen allergens.
A speciﬁc IgE was measured for 6 common allergens in Korea:
Dermatophagoides pteronyssinus, Dermatophagoides farina, egg
whites, cowmilk,German cockroach, andAlternaria alternata.[16]
This study was approved by the Institutional Review Board of
Severance Hospital (protocol no. 4-2004-0036). Informed written
consent for participation was obtained from parents, with verbal
assent from children.22.2. Spirometry and methacholine challenge test
Spirometry and methacholine challenge test were performed by
standardiazed protocols, as we described previously.[17] Spirom-
etry (VIASYS Healthcare, Inc., Conshohocken, PA) was
performed, and ﬂow volume was obtained according to the
American Thoracic Society guidelines before and after BD
inhalation,[18] In a challenge test, each child inhaled increasing
concentrations of methacholine (0.075, 0.15, 0.31, 0.62, 1.25,
2.5, 5, 10, 25, and 50mg/mL) nebulized by a dosimeter (MB3;
Mefar, Brescia, Italy) until FEV1 reduced by 20% from a post-
nebulized saline solution value. The bronchial response was
expressed as the provocative concentration of methacholine
causing a 20% decrease in the FEV1 (PC20; measured in
milligrams per milliliter) and was calculated by linear interpola-
tion of the log dose–response curve.[19]2.3. Sputum induction and processing
For sputum induction and processing, we used the protocol
described by Yoshikawa et al.[20] As we described previously,[17]
all children were instructed to wash their mouths thoroughly with
water. Then, they inhaled a 3% saline solution nebulized in an
ultrasonic nebulizer (NE-U12; Omron Co., Tokyo, Japan) at
maximum output at room temperature. The children were
encouraged to cough deeply at 3-minute intervals thereafter.
Spirometry was repeated after sputum induction. If the FEV1 had
decreased, the child was required to wait until it returned to
baseline values. Sputum samples were kept at 4°C for no more
than 2hours before further processing. A portion of each sample
was diluted with a phosphate-buffered saline solution containing
10mmol/L of dithiothreitol (WAKO Pure Chemical Industries
Ltd, Osaka, Japan) for cell counting. And then, each sample was
gently vortexed for 20minutes at room temperature. After
centrifugation at 400g for 10minutes, the cell pellet was
resuspended. We performed a sputum viability determination
with the trypan blue exclusion method to ensure adequate
viability. Total cell counts were performed with a hemocy-
tometer, and slides were prepared with a cytospin (Cyto-
spin3; Shandon, Tokyo, Japan) and stained with
May–Grünwald–Giemsa stain for differential cell counts.
Differential cell counts were performed by 2 observers who
were blind to the clinical details and who counted 400
nonsquamous cells. The supernatant of each sample was
stored at -70°C for subsequent assay for PTX3.
2.4. Measurement of blood eosinophils, serum total IgE
and ECP, and sputum PTX3
Eosinophils were counted automatically (NE-8000 system;
Sysmex, Kobe, Japan) in peripheral blood, and the serum total
IgE and ECP levels were measured using CAP system (Pharmacia-
Upjohn, Uppsala, Sweden). Sputum PTX3 was individually
detected with enzyme-linked immunosorbent assay kits (R&D
Systems, Minneapolis, MN) according to the manufacturer’s
instructions.The lowerdetection limit of the assaywas0.22ng/mL.2.5. Statistical analysis
Numerical variables were expressed as the mean and standard
deviation (SD). Normal distribution was determined by
Kolmogorov–Smirnov test. Numerical parameters with non-
normal distribution were presented as median and interquartile
range (IQR). Statistical comparison of values between groups
Table 1
Characteristics of subjects.
Characteristics Asthma (n=140) Control (n=120)
Age, y 8.1 (6.6–10.3) 9.3 (7.3–11.4)
Sex, M (%) 95 (66) 77 (61)
Atopy, with (%) 97 (69)
∗
56 (47)
FEV1, % pred 96.6±16.5
∗
105.2±12.2
Change in FEV1, % 7.2±8.1
∗
2.3±4.1
FEV1/FVC, % 84.4±9.1
∗
89.1±5.8
FEF25–75, % pred 78.7±27.9
∗
99.1±23.6
Total IgE, IU/mL 274 (104–684)
∗
113 (47–296)
Blood eosinophil, mL 370 (190–710)
∗
190 (110–350)
Serum ECP, mg/L 25.1 (13.7–44.2)
∗
17.0 (9.0–31.2)
Sputum eosinophil, % 4 (1–15)
∗
0 (0–1)
Values are expressed as number (percentage), mean±SD, or median (interquartile range).
ECP= eosinophil cationic protein, FEF25–75= forced expiratory ﬂow between 25% and 75% of forced
vital capacity, FEV1= forced expiratory volume in 1 second, FVC= forced expiratory vital capacity,
IgE= immunoglobulin E.
∗
P<0.001 compared with control subjects.
Kim et al. Medicine (2016) 95:51 www.md-journal.comwas made by theMann–WhitneyU test. The correlation between
sputum PTX3 concentrations and numerical parameters (blood
eosinophil count; serum total IgE and ECP levels; sputum
eosinophil count; and lung function parameters) was determined
using Spearman rank correlation test. All comparisons were
made by 2-sided. A P value<0.05 was considered statistically
signiﬁcant. Statistical software (SPSS, version 20.0; SPSS Inc,
Chicago, IL) was used for all analyses.3. Results
3.1. Subject characteristics
As summarized in Table 1, there were no signiﬁcant differences in
age or gender between the groups. The percentage of children
with atopy was signiﬁcantly higher in the asthma group than in
the control group (P<0.001). Pulmonary function parameters,
including FEV1 (P<0.001), percentage change in FEV1 after BD
inhalation (P<0.001), ratio of FEV1 and forced vital capacity
(FEV1/FVC) (P<0.001), and forced expiratory ﬂow mid-
expiratory phase between 25% and 75% of FVC (FEF25–75)
(P<0.001), showed signiﬁcantly lower levels in children with
asthma than in control subjects. The blood eosinophil count,
serum ECP, and serum total IgE levels were increased in children
with asthma compared with those in control subjects (P<0.001),
and the percentage of eosinophils in induced sputum was also
increased in children with asthma (P<0.001).AsthmaA BControl
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Figure 1. Comparison of sputum PTX3 levels between groups. (A) Asthmatic child
0.001). (B) Children with moderate-to-severe persistent asthma showed signiﬁcant
and intermittent asthma (P=0.006). The intermittent asthma group and mild per
33.2. Sputum PTX3 and asthma
Sputum PTX3 concentration was signiﬁcantly higher in children
with asthma (328.5pg/mL, 82.34–1312.0pg/mL) than in
control subjects (79.23pg/mL, 29.09–391.40pg/mL, P<0.001)
(Fig. 1A).
Comparing sputum PTX3 levels among the subgroups based
on asthma severity (Fig. 1B), children with moderate-to-severe
persistent asthma showed signiﬁcantly higher sputum PTX3
levels (1190.63pg/mL, 302.70–2619.84pg/mL) than those with
mild persistent asthma (391.72, 73.77–1352.35pg/mL, P=
0.044) and intermittent asthma (188.15pg/mL, 80.41–745.08
pg/mL, P=0.006). The level of sputum PTX3 in the mild
persistent group seemed to be higher than that in the intermittent
asthma group, but there was no statistically signiﬁcant difference
(P=0.27). There were no signiﬁcant differences in age or gender
among the groups (data not shown).3.3. Sputum PTX3 in atopic and allergic inﬂammation
Among the asthmatic children, children with atopic asthma
showed signiﬁcantly higher sputum PTX3 levels (533.57pg/mL,
96.28–1345.87pg/mL) than those with nonatopic asthma
(176.49pg/mL, 61.64–561.97pg/mL, P=0.039) (Fig. 2). Fur-
thermore, the sputum PTX3 levels in the control subjects were
not different between those with atopy (64.59pg/mL,
18.52–201.69pg/mL) and those without atopy (50.70pg/mL,
23.30–304.36pg/mL, P=0.415) (data not shown).
Serum total IgE levels were positively correlated with sputum
PTX3 concentrations (r=0.16, P=0.015) (Fig. 3A). Signiﬁcant
positive correlations were also found between sputum PTX3
levels and serum ECP (r=0.16, P=0.024) (Fig. 3B), blood
eosinophil count (r=0.15, P=0.024) (Fig. 3C), and sputum
eosinophil count (r=0.30, P<0.001) (Fig. 3D).
3.4. Sputum PTX3 in pulmonary function and airway
remodeling
Signiﬁcant negative correlations were observed between sputum
PTX3 and FEV1 (r= -0.30, P=0.001) (Fig. 4A), FEV1/FVC (r= -
0.27, P=0.002) (Fig. 4B), and FEF25–75 (r= -0.392, P<0.001)
(Fig. 4C). Regarding BD response (BDR), signiﬁcant positive
correlation was found (r=0.25, P=0.013) (Fig. 4D).
As shown in Fig. 5, the sputum PTX3 levels were also
signiﬁcantly negatively correlated with post-BD FEV1 (r=0.25,
P<0.001) (Fig. 5A) and post-BD FEV1/FVC (r=0.25, P<
0.001) (Fig. 5B). No signiﬁcant correlationwas observed between
sputum PTX3 levels and PC20 in the methacholine challenge.Intermittent Mild Moderate-to-severe
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Figure 2. Sputum PTX3 levels according to atopic status in asthma patients.
Children with atopic asthma had signiﬁcantly higher levels of sputum PTX3 than
those with nonatopic asthma (P=0.039).
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In this study, sputum PTX3 levels in children with asthma were
signiﬁcantly higher than those in controls. PTX3 levels in sputum
reﬂected atopic status and disease severity. In addition, sputum
PTX3 levels were correlated with other biomarkers and
pulmonary function variables of asthma indicating eosinophilic
airway inﬂammation, decreased pulmonary function, and
persistent airﬂow limitation. Therefore, PTX3 in sputum could
be a surrogate marker to diagnose and assess childhood asthma.
PTX3 has been involved in the modulation of chronic
inﬂammatory diseases produced by various cell types in response
to proinﬂammatory signals.[21] Plasma levels of PTX3 were
found to be markedly higher in patients with cystic ﬁbrosis andFigure 3. Correlation of sputum PTX3 levels with serum total IgE, ECP, blood, and
correlated with the sputum PTX3 concentration. Signiﬁcant positive correlations
eosinophil count, and (D) sputum eosinophil count.
4chronic obstructive pulmonary disease (COPD) than the con-
trol.[10] In COPD patients, an increase of sputum PTX3 levels was
well correlated with symptom scores.[11] And the PTX3 levels in
sputum was an independent biomarker associated with COPD
severity.[12] Furthermore, increased PTX3 protein production in
bronchial tissue, mainly in airway smooth muscle cells (AMSCs),
was initially reported in adult asthmapatients.[14] An in vitro study
reported that the release of PTX3 from human AMSCs was
stimulated by proinﬂammatory cytokines [interleukin (IL)-1b,
tumor necrosis factor (TNF)], and PTX3 enhanced the release of
C-C motif chemokine ligand 11 (CCL11)/eotaxin-1, which is an
important chemokine in eosinophilic airway inﬂammation and
remodeling. It is inferred that PTX3 may be involved in the
pathogenesis of asthma, with the induction of CCL11/eotaxin-1
expression in inﬂammatory conditions affecting structural alter-
ations in asthmatic airways.[14] However, the association between
PTX3 and childhood asthma or involvement of PTX3 in
development of childhood asthma has not yet been established.
We found that the sputum PTX3 concentration was
signiﬁcantly elevated in asthmatic children compared with
controls, consistent with previous reports in adults. Children
with moderate-to-severe persistent asthma showed signiﬁcantly
higher PTX3 levels in sputum than those with intermittent and
mild persistent asthma. Among the asthma patients, sputum
PTX3 was increased in children with atopy. Sputum PTX3 levels
showed signiﬁcant positive correlations with serum total IgE,
ECP, and eosinophil counts in the blood and sputum, which are
well-known biomarkers of atopic status, asthma severity, and
eosinophilic airway.[21,22]
Current guidelines recommend pre- and post-BD spirometry in
children above 5 years of age for diagnosis, classiﬁcation of
severity, and assessment of asthma control.[15] Although FEV1
has been considered an objective and reproducible value forsputum eosinophil counts in asthma patients. (A) Serum total IgE was positively
were also found between sputum PTX3 levels and (B) serum ECP, (C) blood
Figure 4. Correlation of sputum PTX3 concentration with pulmonary function variables and bronchodilator response (BDR). Sputum PTX3 concentrations were
negatively correlated with (A) FEV1, (B) FEV1/FVC, and (C) FEF25–75. (D) A signiﬁcant positive correlation was found between sputum PTX3 levels and BDR.
Kim et al. Medicine (2016) 95:51 www.md-journal.commeasuring airway obstruction, FEV1 is often normal even in
children with uncontrolled asthma.[23,24] Therefore, other
pulmonary function variables have been considered. The
FEV1/FVC ratio may be a more sensitive indicator of airﬂow
obstruction in children to complement FEV1.
[14] Recently, low
FEF25–75,which reﬂects small airway patency, was found to be
associated with increased asthma severity in children.[25] BDR, a
response to short-acting beta agonist, has been suggested as a
surrogate biomarker of airway inﬂammation to predict clinical
outcomes and the response to treatment in children with
asthma.[26] In addition, low values for post-BD FEV1 and
post-BD FEV1/FVC are regarded as functional markers of
structural changes that could reﬂect persistent airﬂow limita-
tion.[27] However, pulmonary function parameters are limited by
their poor correlations with asthma phenotypes and symptom-
based severity in children,[26] and children can have persistent
airﬂow limitations and structural changes regardless of pheno-
type.[28,29] In addition, general application of bronchoscopy, the
gold standard to evaluate airway remodeling is also difﬁcult inFigure 5. Correlation of sputum PTX3 levels with post-bronchodilator (BD) FEV1 a
with post-BD FEV1and (B) post-BD FEV1/FVC.
5children because of its invasiveness. Therefore, there is a need to
identify new surrogate markers for use in these patients.
We investigated sputum PTX concentration to determine its
applicability for diagnosis, assessment, and monitoring of
childhood asthma. Sputum PTX3 levels showed signiﬁcant
negative correlations with FEV1, FEV1/FVC ratio, and FEF25–75
and a positive correlation with BDR. Increased sputum PTX3
levels in asthmatic children could indicate poor lung function,
with decreased values for the FEV1 and FEV1/FVC ratio
indicating current airway obstruction.[26,30] In addition, low
FEF25–75 and increased BDR may predict worse clinical
outcomes.[25,26] Sputum PTX3 expression was negatively
correlated with post-BD pulmonary function. Previous studies
suggest that a low post-BD FEV1 and post-BD FEV1/FVC ratio
reﬂect persistent airﬂow limitation and irreversible structural
changes of the bronchial wall.[27,30,31]
This is the ﬁrst clinical study to evaluate PTX3 levels in induced
sputum of children with asthma. Increased levels of PTX3 in
induced sputum could indicate atopic status, current asthma andnd FEV1/FVC. (A) Sputum PTX3 levels showed signiﬁcant negative correlation
[13] Van Pottelberge GR, Bracke KR, Pauwels NS, et al. COPD is associated
Kim et al. Medicine (2016) 95:51 Medicineits severity, and characteristics of asthma, such as eosinophilic
inﬂammation, decreased lung function, persistent airﬂow limita-
tion, and airway remodeling. These results suggest that PTX3
levels in sputum could be useful for diagnosing and assessing
childhood asthma. However, there are a few limitations of this
study. We could not investigate the relationship between sputum
PTX3 levels and treatment in asthmatic children because
asthmatic children did not receive maintenance therapy at the
time of enrollment in this study. Furthermore, the correlations
between sputum PTX3 and measurements of atopy and
pulmonary function were seemed to be weak although statisti-
cally signiﬁcant, whichmight be due to the limitation of the cross-
sectional design. Additional prospective clinical trials are
necessary to better understand the clinical utility of PTX3 in
the diagnosis, classiﬁcation of phenotypes, and treatment of
asthma in children.References
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